Table 3 Sensitivity analyses by random versus fixed effects for serious infection risk by comparison of significant estimates between random and fixed effects models

TAC vs. glucocorticoids

0.33 (0.12–0.88)

0.33 (0.13–0.82)

TAC vs. CYC

0.37 (0.15–0.87)

0.37 (0.16–0.82)

TAC vs. MMF

0.40 (0.18–0.81)

0.40 (0.20–0.78)

TAC vs. AZA

0.32 (0.12–0.81)

0.32 (0.13–0.77)

CYC LD vs. TAC

4.84 (1.48–17.64)

4.50 (1.43–14.50)

HD glucocorticoids vs. TAC

12.83 (1.53–119.90)

12.22 (1.58–105.70)

CYC HD vs. TAC

6.60 (2.25–20.50)

6.52 (2.38–18.95)

MMF-AZA vs. CYC LD

0.09 (0.01–0.76)

0.09 (0.01–0.74)

MMF-AZA vs. HD glucocorticoids

0.03 (0.00–0.56)

0.21 (0.02–1.79)

MMF-AZA vs. CYC HD

0.07 (0.01–0.54)

0.07 (0.01–0.47)

MMF-AZA vs. CYC-AZA

0.14 (0.02–0.71)

0.14 (0.02–0.65)

Residual deviance

72.49

74.9

Number of unconstrained data points

71

71

Deviance information criteria

325.646

325.51